This is a preview of subscription content, log in via an institution to check access.
References
Veenstra DL, et al. Is erlotinib for first-line use in EGFR+ non-small-cell lung cancer cost-effective? 49th Annual Meeting of the American Society of Clinical Oncology : abstr. e19001, 31 May 2013. Available from: URL: http://meetinglibrary.asco.org/content/117352-132
Jones T, et al. The economic assessment of eribulin compared to treatment of physician's choice (TPC) in Australia. 49th Annual Meeting of the American Society of Clinical Oncology : abstr. e17552, 31 May 2013. Available from: URL: http://meetinglibrary.asco.org/content/114679-132
Ko Y-J, et al. A cost-utility analysis of gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer. 49th Annual Meeting of the American Society of Clinical Oncology : abstr. e17569, 31 May 2013. Available from: URL: http://meetinglibrary.asco.org/content/116476-132
Bentley TG, et al. Impact of the 92-gene assay on cost of diagnosis of tumor type in metastatic cancer of uncertain origin. 49th Annual Meeting of the American Society of Clinical Oncology : abstr. e15104, 31 May 2013. Available from: URL: http://meetinglibrary.asco.org/content/115757-132
Graham DM, et al. A preliminary cost-effectiveness analysis of human papillomavirus vaccination in males for the prevention of oropharyngeal cancer. 49th Annual Meeting of the American Society of Clinical Oncology : abstr. 6033, 31 May 2013. Available from: URL: http://meetinglibrary.asco.org/content/111521-132
Rights and permissions
About this article
Cite this article
News from ASCO. PharmacoEcon Outcomes News 681, 4–5 (2013). https://doi.org/10.1007/s40274-013-0502-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0502-7